Crowdonomics
Algernon Neuroscience Inc.

Reg A+ · Equity · Jan 2025

WithdrawnReg A+Equity
via Netcapital · last checked Aug 16, 2026
Raised
$0 / $5M max
0% of ceiling
Investors
—
—
Estimated pre-money
$10M
—

Financials disclosed in this offering

FY2023 · hover for source
$0
−$752K
FY2023
RevenueNet income
Metric
FY2023 audited
Income statement
Revenue
$0
Cost of goods sold
$749,254
Net income
-$751,782
Balance sheet
Cash
$1
Accounts receivable
$0
Total assets
$39,964
Long-term debt
$0
Total liabilities
$1,655,031
Other
Headcount
0

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Apr 2, 2025
    Amended during SEC review — offering terms unchanged
    Form 1-A/A on EDGAR ↗
  2. Mar 6, 2025
    Amended during SEC review — offering terms unchanged
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$10M
Price / share$0.50
Shares offered12,000,000

Estimated, not stated: $0.50 × 20,000,001 securities outstanding.

Offering details

Target—
Max$5,000,000
Min investment—
OpenedJan 24, 2025
Deadline—
ClosedApr 13, 2026
Days active444

Links & provenance

Source: SEC EDGAR
0001062993-25-001035
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.